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INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is a naturally occurring peptide hormone that is released from intestinal L-cells in response to nutrient ingestion. GLP-1 lowers blood glucose levels in both preclinical studies and in human subjects with type 2 diabetes through multiple distinct actions including stimulation of glucose-dependent insulin secretion, suppression of glucagon secretion, and inhibition of gastric emptying 1, 2 .
GLP-1 also promotes satiety, suppresses energy intake and causes weight loss in healthy, obese and diabetic humans. In preclinical studies, GLP-1 increases β-cell mass via induction of β-cell proliferation and neogenesis and inhibition of β-cell apoptosis [3] [4] [5] . The combined properties of GLP-1 to reduce glycemia and promote weight loss, in association with its potential to restore or sustain β-cell mass and function, have sparked considerable interest in the use of GLP-1 as a therapeutic agent for the treatment of type 2 diabetes (T2DM) 6 .
A major limitation to the therapeutic use of the native GLP-1 molecule is its very short half-life in the circulation, which has been attributed to both rapid cleavage by the ubiquitous proteolytic enzyme dipeptidyl peptidase-4 (DPP-4) and renal clearance. Consequently, GLP-1 must be injected repeatedly or infused continuously to sustain clinical efficacy in vivo. Thus, pharmaceutical strategies based on sustained GLP-1
receptor (GLP-1R) activation have been focused on the development of long-acting DPP-4-resistant GLP-1R
agonists such as exenatide and liraglutide. Exenatide is a synthetic version of the lizard salivary gland-derived peptide exendin-4 (Ex-4) that is resistant to DPP-4 7 .
Preclinical and clinical studies demonstrate that exenatide is a long-acting GLP-1R agonist 8, 9 and it has been approved for clinical use in the United States and Europe.
Liraglutide is a DPP-4-resistant fatty-acylated GLP-1 peptide analog that binds noncovalently to serum albumin following subcutaneous administration, thereby reducing its renal clearance and extending its pharmacokinetic profile 10 . Liraglutide exhibits more potent and persistent glucose-lowering effects in diabetic patients compared to native GLP-1 and is currently undergoing evaluation in phase 3 clinical trials in patients with T2DM.
Although exenatide and liraglutide effectively lower blood glucose levels in type 2 diabetic patients, the requirement for twice-or once-daily administration of these agents, respectively, has fostered ongoing efforts to generate GLP-1R agonists with more sustained effectiveness. One such putative agent is CJC-1134-PC, a conjugate consisting of Ex-4 that has been covalently bonded, ex vivo, to recombinant human serum albumin Animals. Wild-type C57BL/6 mice (4-or 7-weeks-old) were from Charles River Laboratories (Montreal, QC).
Glp1r-/-mice on the CD-1 genetic background have been described 12 . Glp1r-/-mice back-crossed onto the C57BL/6 genetic background for six generations 13 were used in the current studies. pm. For mice receiving once daily injections, drugs were administered in the evening but mice were also given ip injections of PBS in the morning to ensure that all mice were exposed to identical experimental conditions. Biochemical assays. Blood glucose levels in whole blood were measured using a Glucometer Elite blood glucose meter (Bayer, Toronto, ON). Plasma insulin levels were measured using a Rat/Mouse Insulin ELISA kit (LINCO Research, St. Charles, MO) and pancreatic insulin levels were determined using a Rat insulin RIA In vitro cAMP production. Baby hamster kidney (BHK) fibroblast cells stably transfected with the rat GLP-1R 5 were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). Cells were incubated with 1 Measurement of gastric emptying rate. The rate of gastric emptying was determined as described in 14 4 hours after peptide injections. The gastric emptying rate was calculated using the following equation: gastric emptying rate (%) = [1-(stomach content wet weight/food intake)] x 100.
Evaluation of c-Fos immunoreactivity in the murine CNS. The number of c-Fos immunopositive neurons
was quantified in regions of the mouse CNS as described 15, 16 . Sections were processed for immunocytochemical detection of Fos using an avidin-biotin-immuno peroxidase method (Vectastain ABC Elite Kit, Vector Laboratories, Burlingame, CA) as described 17 Body composition. Total body fat and lean mass were measured using a mouse whole-body magnetic resonance analyzer (Echo Medical Systems, Houston, TX).
β-cell mass determination. Pancreatic sections were immunostained for insulin as described 13 . Morphometric measurements of insulin-positive area and total pancreatic area were determined using ImageScope software (Aperio Technologies Inc., Vista, CA) and β-cell mass was calculated using the following equation: (insulin positive area/total pancreatic area) x pancreas weight. For each pancreas sample, the β-cell mass was averaged from two different slides that were obtained from the same pancreas sectioned at two different levels.
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ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T Hepatic lipids. For histological examination of hepatic lipids, the liver was removed, embedded in Tissue-Tek OCT Compound (Sakura Finetek, Torrence, CA), frozen rapidly in a dry ice/ethanol bath and stored at -80ºC.
Frozen tissue was cut into 8 µm sections and stained with oil-red-O using standard protocols. For hepatic lipid determinations, hepatic lipids were extracted as described in 19 .
RNA isolation and real-time PCR. RNA was extracted from pancreas samples using TRI reagent (Sigma, St.
Louis, MO) and first-strand cDNA generated using standard protocols. Primers and PCR conditions for the selected genes were those recommended by Applied Biosystems. Relative mRNA levels were quantified using the 2 -∆Ct method 20 .
Statistical analysis. All data are presented as means ± SE. Statistical significance was determined by One-or Two-way ANOVA and Bonferroni's post hoc test using Prism version 4.02 software (GraphPad Software, San Diego, CA). A P value <0.05 was considered to be statistically significant. CJC-1134-PC significantly reduced food intake in wild-type mice ( Fig. 2 ) and the effect of CJC-1134-PC and Ex-4 to decrease feeding lasted for at least 24 h (Fig. 2 A) . Moreover, at 4-8 h and 8-24 h following injection, the reduction in food intake was significantly greater with CJC-1134-PC compared to Ex-4 ( Fig. 2 ).
A C C E P T E D
The anorectic action of CJC-1134-PC was not simply a non-specific aversive response as it required a functional GLP-1 receptor ( Fig. 2A inset) .
The mechanisms through which GLP-1 regulates gastric emptying remain incompletely understood and may require interaction with neural pathways 21, 22 . Both Ex-4 and CJC-1134-PC significantly diminished the gastric emptying rate in wild-type mice ( Fig. 2B ), but not in Glp1r-/-mice ( Fig. 2C ). In contrast, CCK-8, which inhibits gastric emptying through a distinct mechanism, significantly reduced the gastric emptying rate in Glp1r-/-mice ( Fig. 3 ). Non-fasting blood glucose levels in HFD-fed CJC-1134-PC-and Ex-4-treated mice were lower compared to control mice (Fig. 4A) . Mice on the HFD gained more weight compared to mice maintained on the normal chow diet during the first 4 wks (Fig. 4B) . However, HFD-fed mice treated with CJC-1134-PC or Ex-4 lost weight and, after 4 weeks of treatment, mice treated with CJC-1134-PC had body weights similar to normal chow-fed PBS-treated mice (Fig. 4B ). Serum Hb A1c levels were reduced in HFD-fed mice treated with CJC-1134-PC, but not Ex-4 ( Fig. 4C ).
Chronic administration of Ex-4 or CJC-1134-PC in HFD-fed mice produced significant reductions in glucose excursions following glucose challenge (Fig. 5A,B and D,E) and CJC-1134-PC but not Ex-4, increased insulin-to-glucose ratios measured following glucose administration ( Fig. 5C and F) . Chronic treatment with CJC-1134-PC or Ex-4 had no effect on plasma glucagon levels measured in these same samples (data not shown). Both Ex-4 and CJC-1134-PC reduced body weight and fat mass in HFD-fed mice and MRI data demonstrated that Ex-4 and CJC-1134-PC reduced total and percent body fat mass and increased percent lean mass relative to HFD-fed control treated mice ( Fig. 6A and B) . Furthermore, body weight and epididymal fat pad weights were significantly decreased in CJC-1134-PC-and Ex-4-treated HFD-fed mice, and were comparable to those observed in PBS-treated mice maintained on a normal chow diet ( Fig. 6C and data not shown).
CJC-1134-PC or Ex-4 had no effect on serum MCP-1 or PAI-1 levels in HFD-fed mice ( Fig. 7A and B) , whereas treatment with Ex-4, but not CJC-1134-PC, led to significant reductions in serum resistin (Fig. 7C ).
Serum leptin levels were significantly lower in both CJC-1134-PC-and Ex-4-treated mice (Fig. 7D ).
Serum cholesterol levels were reduced in HFD-fed mice following administration of CJC-1134-PC, but not Ex-4 ( Fig. 8 A) . Surprisingly, chronic treatment with both CJC-1134-PC and Ex-4 resulted in significant elevations in serum triglyceride levels (Fig. 8B) . Although hepatic cholesterol levels were unchanged (data not shown), total hepatic triglyceride content was reduced following treatment with CJC-1134-PC or Ex-4 in HFD-fed mice ( Fig. 8D-F) . Conversely, CJC-1134-PC or Ex-4 administration did not alter the mRNA levels of apolipoprotein B, hepatic lipase, PPARα or Srebf1 (data not shown).
Chronic administration of CJC-1134-PC up-regulates expression of β-cell specific genes and increases pancreas weight but has no effect on β-cell mass in HFD-fed mice.
Ex-4, but not CJC-1134-PC, increased insulin mRNA levels compared to saline-treated mice ( Supplementary Fig. 5A ). In contrast, pancreas insulin content was significantly reduced in CJC-1134-PCtreated mice relative to levels in mice treated with HSA but was not significantly different in Ex-4-vs. controltreated mice ( Supplementary Fig. 5B ). Although both CJC-1134-PC and Ex-4 increased pancreas weights in HFD-fed mice ( Supplementary Fig. 5C ), no significant increases in β-cell mass were observed following chronic treatment with either agent (Supplementary Fig. 5D ). GLP-1R agonists also increase the expression of genes that contribute to β-cell glucose sensing, proliferation, neogenesis or cytoprotection 2, 26, 27 . mRNA levels of Gck, Glp1r, and Pdx1 were increased in pancreatic RNA from both CJC-1134-PC-and/or Ex-4-treated mice.
( Supplementary Fig. 5E-G) . Surprisingly however, Ex-4, but not CJC-1134-PC, markedly increased levels of mRNA transcripts for Irs2 (Supplementary Figure 5H) . . As large proteins like albumin cannot readily cross an intact blood-brain barrier 31 , the ability of CJC-1134-PC to inhibit food intake and gastric emptying suggests that GLP-1R agonists do not require direct access to the CNS to mediate
A C C E P T E D M A N U S C R I P T
these effects, and are in agreement with data demonstrating that GLP-1 and/or Ex-4 modify feeding and gut motility via the vagus 21, 32, 33 . These results are corroborated by the demonstration that peripherally administered CJC-1134-PC activates c-fos expression in the murine CNS, and produces weight loss in mice.
Hence, high molecular weight GLP-1R agonists such as CJC-1134-PC remain capable of activating circuits regulating gastric emptying and satiety in a GLP-1R-dependent manner.
In humans, GLP-1 or Ex-4 treatment has been associated with significant reductions in post-prandial plasma triglyceride levels whereas chronic treatment with either CJC-1134-PC or Ex-4 led to significantly increased non-fasting plasma triglyceride levels but reduced hepatic lipid content. These results highlight key differences between the control of murine vs. human hepatic lipid homeostasis. Real-time PCR analysis revealed that CJC-1134-PC-and Ex-4-treatment reduced hepatic levels of genes that encode proteins involved in hepatic lipid uptake and intracellular transport (CD36, Fabp1, Fabp2), suggesting that lipids are being diverted from the liver.
Although demonstrated that GLP-1R agonists increase β-cell mass in diabetic rodents, we detected no increase in β-cell mass in HFD-fed mice that were treated chronically with CJC-1134-PC or Ex-4. Since HFDfeeding can lead to either no changes or increases in β-cell mass to compensate for HFD-induced insulin resistance 34, 35 , it is possible that the replicative capacity of the β-cell is maximized in our studies and cannot 
